BI-2536 is a potent inhibitor of PLK1 (Polo-like kinase 1, IC50?~0.83 nM) and BRD4 (IC50?~37 nM).? It also inhibits PLK2 and PLK3 with IC50?of 3.5 nM and 9.0 nM, respectively. BI-2536 treatment ranging from 10 nM to 100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, and other Plk1 dependent processes. BI-2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50?of 2-25 nM. It also displaces BRD4 from chromatin and suppresses c-Myc expression. The combination of inhibitory activities on independent kinase and bromodomain oncogenic pathways exemplifies a new strategy for rational single-agent polypharmacological targeting.?
?
How to Use:
In vitro:? BI-2536 was used at 0.1-1 μM in vitro.
In vivo:??BI-2536 was dosed to mice by IV injection at 50 mg/kg once or twice a week in xenograft models. (Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl)
Reference:?
? ?
Products are for research use only. Not for human use.
BIOLEAF熱搜 BIOLEAF試劑盒 BIOLEAF ELISA BIOLEAF試劑 BIOLEAF品牌 BIOLEAF抗體 BIOLEAF耗材 BIOLEAF小儀器
sitemap 細胞庫查詢 危險品圖標 本公司網站所展示銷售的產品僅供科研！
滬公網安備 31011202007338號
